TJ081

TJ081 is a small molecule therapeutic candidate being developed by Tuojie Biotech (Suzhou Tuojie Biotechnology) for the treatment of muscle diseases. As of 2024, the program is in the IND-enabling stage, representing a key asset in the sponsor's pipeline focused on muscle-targeted drug discovery. Tuojie Biotech specializes in developing small molecule interventions for neuromuscular disorders and conditions involving muscle atrophy or dysfunction, aiming to modulate pathways that regulate muscle mass and health. While the specific biological target of TJ081 has not been publicly disclosed, it is part of a broader effort by the developer to address unmet needs in muscle-related pathologies.

Other names

TJ081TJ-081TJ 081